Home › Compare › GLAE vs MRK

GLAE vs MRK: Dividend Comparison 2026

GLAE yields 7.14% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GLAE wins by $1.3K in total portfolio value
10 years
GLAE
GLAE
● Live price
7.14%
Share price
$28.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.1K
Annual income
$1,124.05
Full GLAE calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — GLAE vs MRK

📍 GLAE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGLAEMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GLAE + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
GLAE pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GLAE
Annual income on $10K today (after 15% tax)
$607.14/yr
After 10yr DRIP, annual income (after tax)
$955.44/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, GLAE beats the other by $147.70/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GLAE + MRK for your $10,000?

GLAE: 50%MRK: 50%
100% MRK50/50100% GLAE
Portfolio after 10yr
$31.4K
Annual income
$1,037.18/yr
Blended yield
3.30%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

GLAE
No analyst data
Altman Z
-63.0
Piotroski
4/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GLAE buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGLAEMRK
Forward yield7.14% ✓3.25%
Annual dividend / share$2.00$3.08 ✓
Payout ratio50%42% ✓
1-year div growth0%5.5% ✓
5-year div CAGR0%8.2% ✓
Portfolio after 10y$32.1K ✓$30.7K
Annual income after 10y$1,124.05 ✓$950.29
Total dividends collected$9.2K ✓$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GLAE vs MRK ($10,000, DRIP)

YearGLAE PortfolioGLAE Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,414$714.29$11,192$351.54+$222.00 → GLAE
2$12,975$761.97$12,524$392.70+$451.00 → GLAE
3$14,693$809.51$14,015$438.65+$678.00 → GLAE
4$16,578$856.71$15,682$489.96+$896.00 → GLAE
5$18,642$903.39$17,547$547.23+$1.1K → GLAE
6$20,896$949.40$19,632$611.16+$1.3K → GLAE
7$23,354$994.59$21,963$682.53+$1.4K → GLAE
8$26,027$1,038.83$24,571$762.18+$1.5K → GLAE
9$28,931$1,082.01$27,486$851.08+$1.4K → GLAE
10$32,081$1,124.05$30,745$950.29+$1.3K → GLAE

GLAE vs MRK: Complete Analysis 2026

GLAE — Stock

GlassBridge Enterprises, Inc., through its subsidiaries, owns and operates an asset management business in the United States. It offers investment advisory services to third party investors through managed funds, as well as separate managed accounts. The company was formerly known as Imation Corp. and changed its name to GlassBridge Enterprises, Inc. in February 2017. GlassBridge Enterprises, Inc. was incorporated in 1996 and is headquartered in New York, New York.

Full GLAE Calculator →

MRK — Healthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this GLAE vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GLAE vs SCHDGLAE vs JEPIGLAE vs OGLAE vs KOGLAE vs MAINGLAE vs JNJGLAE vs ABBVGLAE vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.